06:02 EST Gilead (GILD) to acquire Arcellx (ACLX) for $115 per share in cash at closing, or $7.8B
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead initiated with an Equal Weight at Barclays
- Gilead price target raised to $170 from $140 at Mizuho
- Gilead Sciences: Strong HIV Growth Priced In, Diversification Still Limited Justifying Hold Rating
- Gilead price target raised to $175 from $155 at UBS
- XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?